---
title: "CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284559073.md"
description: "CSPC Pharmaceutical Group has received FDA approval for its SYS6051 antibody-drug conjugate, allowing clinical trials in the U.S. It also secured clearance from China's National Medical Products Administration for trials in advanced solid tumors. Preclinical studies indicate strong anti-tumor activity, enhancing CSPC's oncology pipeline and competitive position. Analysts rate the stock (HK:1093) as a Buy with a price target of HK$13.05. CSPC focuses on innovative therapies and operates globally, listed on the Hong Kong Stock Exchange with a market cap of HK$101.3B."
datetime: "2026-04-29T11:25:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284559073.md)
  - [en](https://longbridge.com/en/news/284559073.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284559073.md)
---

# CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.

CSPC Pharmaceutical Group has received U.S. Food and Drug Administration approval for an Investigational New Drug application covering SYS6051, an antibody-drug conjugate targeting tissue factor on tumor cells, enabling clinical trials in the U.S. SYS6051 also secured clearance from China’s National Medical Products Administration in April 2026 for clinical trials in advanced solid tumors.

Preclinical studies showed SYS6051 delivered strong anti-tumor activity across various cancers, supporting expectations of favorable therapeutic effects as human trials begin. The dual approvals in the U.S. and China strengthen CSPC’s oncology pipeline and global R&D footprint, potentially enhancing its competitive position in antibody-drug conjugates and expanding future treatment options for patients with advanced solid tumors.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

**More about CSPC Pharmaceutical Group**

CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on developing innovative therapies, including biologics and oncology drugs. The group operates through multiple subsidiaries and targets major global markets, with its shares listed on the Stock Exchange of Hong Kong under stock code 1093.

**Average Trading Volume:** 102,317,891

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$101.3B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharmaceutical Grants 46.5 Million Restricted Shares to 727 Employees](https://longbridge.com/en/news/273529699.md)
- [CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone](https://longbridge.com/en/news/286244356.md)
- [Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus | OTLC Stock News](https://longbridge.com/en/news/286276734.md)
- [11:46 ETFirst-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer](https://longbridge.com/en/news/286128397.md)
- [Small study shows one-time cell therapy can control HIV infection](https://longbridge.com/en/news/286002405.md)